Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Menditto, E (Author) Other; Orlando, V (Author) Other; De Rosa, G (Author) Other; Minghetti, P (Author) Other; Musazzi, UM (Author) Other; Cahir, C (Author) Other; Kurczewska Michalak, M (Author) Other; Kardas, P (Author) Other; Costa, E (Author) FFUP; Sousa Lobo JM (Author) FFUP; Almeida, IF (Author) FFUP

Journal

Title: Pharmaceutics

Vol. 12

Final page: 44

ISSN: 1999-4923

Publisher: MDPI

Indexing

ISI Web of Knowledge - 37 Citations

Scopus - 43 Citations

Other information

Authenticus ID: P-00R-N16

DOI: 10.3390/pharmaceutics12010044

Abstract (EN): Medication adherence is a growing concern for public health and poor adherence to therapy has been associated with poor health outcomes and higher costs for patients. Interventions for improving adherence need to consider the characteristics of the individual therapeutic regimens according to the needs of the patients. In particular, geriatric and paediatric populations as well as dermatological patients have special needs/preferences that should be considered when designing drug products. Patient Centric Drug Product Pharmaceutical Design (PCDPD) offers the opportunity to meet the needs and preferences of patients. Packaging, orodispersible formulations, fixed dose combinations products, multiparticulate formulations, topical formulations and 3D printing are of particular relevance in a PCDPD process. These will be addressed in this review as well as their impact on medication adherence.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 23